Skip to main content

Table 2 CIK cells therapy-related adverse events according to category and grade

From: PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

Category Patients no.(%) Time to Onset(hours), Median (range) Time of duration(hour), Median (range)
Total Grade 1–2 Grade 3–4 treatments
Any 12(8.0) 11(7.3) 1(0.7) 2(1.3) 4.5(0.5–30.0) 12(0.5–36.0)
Fever 4(2.7) 3(2.0) 1(0.7) 1(0.7) 3.75(2.5–6.0) 6.75(2.0–12.0)
Chill 4(2.7) 4(2.7) NA NA 2.0(1.5–4.5) 1.25(0.5–2.0)
Rash NA NA NA NA   
Pruritus NA NA NA NA   
Arthralgia/myalgia 3(2.0) 3(2.0) NA NA 12.0(8.0–20.0) 24.0(12.0–36.0)
Fatigue 3(2.0) 3(2.0) NA NA 6.0(4.0–12.0) 18.0(12.0–24.0)
Anorexia 3(2.0) 3(2.0) NA NA 20.0(6.0–30.0) 20.0(12.0–36.0)
Nausea/vomiting 1(0.7) 1(0.7) NA NA 1.5(NA) 12.0(NA)
Allergic reaction NA NA NA NA   
Hypertension 1(0.7) 1(0.7) NA 1(0.7) 0.5(NA) 1.5(NA)
Pneumonitis NA NA NA NA   
Hepatitis NA NA NA NA   
Colitis NA NA NA NA   
  1. Abbreviations: NA Not applicable